News
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 million ...
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...
CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...
1d
TipRanks on MSNPfizer’s Updated COVID-19 Vaccine Study: What Investors Need to Know
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled ‘Estimated Vaccine Effectiveness ...
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac US$740 ...
In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a ...
While Pfizer projected that 2021 sales for the Covid-19 vaccine would be around $15 billion during its Q4 2020 earnings update back in February, it’s quite likely that sales will exceed this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results